SFG Wealth Management LLC. Has $343,000 Holdings in Pfizer Inc. $PFE

SFG Wealth Management LLC. grew its position in Pfizer Inc. (NYSE:PFE) by 6.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,138 shares of the biopharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. SFG Wealth Management LLC.’s holdings in Pfizer were worth $343,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in PFE. Bessemer Group Inc. boosted its holdings in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 13,228 shares during the period. Capital Advisors Inc. OK boosted its stake in shares of Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after buying an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new stake in Pfizer during the first quarter worth approximately $8,283,000. Westbourne Investments Inc. bought a new position in Pfizer during the 1st quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. raised its holdings in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.35.

Pfizer Trading Down 0.8%

Shares of Pfizer stock opened at $24.53 on Wednesday. The firm’s 50 day moving average is $24.88 and its 200 day moving average is $24.12. The firm has a market capitalization of $139.44 billion, a PE ratio of 13.05, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.